Evidence map›Paper›PMID 30938285›Full record

ArticleThe American journal of tropical medicine and hygiene2019

Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?

Irene Losada Galván, Olaya Madrid Pascual, Juan María Herrero-Martínez, Ana Pérez-Ayala, Manuel Lizasoain Hernández

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Human Histatin 5 Exerts Anti-Trypanosomal Activity AgainstInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Observational
  5. Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole.Revista da Sociedade Brasileira de Medicina Tropical · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Irene Losada GalvánInternal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Olaya Madrid PascualInternal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Juan María Herrero-MartínezInternal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Ana Pérez-AyalaMicrobiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Manuel Lizasoain HernándezInternal Medicine Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this retrospective cohort study, we aimed to assess whether introducing benznidazole at escalating doses reduces the probability of adverse events or treatment discontinuation compared with a full-dose scheme. We collected data from patients who had chronic

Indexed as

AdultChagas DiseaseCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansMaleMiddle AgedNitroimidazolesRetrospective StudiesTrypanocidal AgentsbenzonidazoleNitroimidazolesTrypanocidal Agents

Identifiers

PMID30938285
PMCPMC6553914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.